文献速递前列腺癌

直肠指检与前列腺特异性抗原作为前列腺癌筛查试验的性能比较:系统综述与Meta分析

Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2024-01-04

该系统综述与Meta分析纳入8项前瞻性研究共85798名参与者,比较直肠指检(DRE)与前列腺特异性抗原(PSA)筛查前列腺癌的诊断性能。DRE的汇总阳性预测值(PPV)为0.21,与PSA的0.22相似,联合检测未获益;但DRE的癌症检出率(CDR)为0.01,显著低于PSA的0.03及联合检测的0.03。作者认为在无临床症状和体征时,DRE可考虑从前列腺癌筛查和早期检测策略中省略。

要点

  • DRE的汇总PPV为0.21,与PSA的0.22相似,联合检测PPV为0.19,无额外获益。
  • DRE的CDR为0.01,显著低于PSA的0.03和联合检测的0.03。
  • 作者认为在无临床症状和体征时,DRE可考虑从前列腺癌筛查策略中省略。

核心结论

  • 作为独立检测或PSA的补充措施,DRE在前列腺癌检测中诊断价值显著较低。
  • 在无临床症状和体征时,DRE可考虑从前列腺癌筛查和早期检测策略中省略。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Scopus和Web of Science数据库(2023年8月),纳入8项前瞻性研究共85798名参与者,其中3项为随机对照试验、5项为前瞻性诊断研究,均同时报告DRE和PSA在同一队列中的PPV和CDR。
  • 主要终点为DRE的PPV和CDR,次要终点为单独PSA及PSA联合DRE的PPV和CDR,采用Meta回归分析比较不同筛查策略。
  • 该Meta分析已在PROSPERO注册(CRD42023446940)。

主要发现

  • DRE的汇总PPV为0.21(95%CI 0.13-0.33),与PSA的PPV 0.22(95%CI 0.15-0.30;p=0.9)相似。
  • DRE联合PSA的PPV为0.19(95%CI 0.13-0.26;p=0.5),联合检测未显示获益。
  • DRE的CDR为0.01(95%CI 0.01-0.02),显著低于PSA的0.03(95%CI 0.02-0.03;p<0.05)及联合检测的0.03(95%CI 0.02-0.04;p<0.05)。
  • DRE联合PSA与单独PSA在CDR(p=0.5)和PPV(p=0.5)方面无差异。

临床怎么用

  • 作者认为,在无临床症状和体征时,DRE可考虑从前列腺癌筛查和早期检测策略中省略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Although digital rectal examination (DRE) is recommended in combination with prostate-specific antigen (PSA) for detection of prostate cancer (PCa), there are limited data to support its use as a screening/early detection test. Our objective was to assess the diagnostic value of DRE in screening for early detection of PCa. METHODS: In August 2023, we queried the PubMed, Scopus, and Web of Science databases to identify prospective studies simultaneously investigating the diagnostic performance of DRE and PSA for PCa screening. The primary endpoints were the positive predictive value (PPV) and cancer detection rate (CDR) of DRE. Secondary endpoints included the PPV and CDR of both PSA alone and in combination with DRE. We conducted meta-regression analysis to compare the CDR and PPV of different screening strategies. This meta-analysis is registered on PROSPERO (CRD42023446940). KEY FINDINGS AND LIMITATIONS: We identified eight studies involving 85,798 participants, of which three were randomized controlled trials and five were prospective diagnostic studies, that reported the PPV and CDR of both DRE and PSA for the same cohort. Our analysis revealed a pooled PPV of 0.21 (95% confidence interval [CI] 0.13-0.33) for DRE, which is similar to the PPV of PSA (0.22, 95% CI 0.15-0.30; p = 0.9), with no benefit from combining DRE and PSA (PPV 0.19, 95% CI 0.13-0.26; p = 0.5). However, the CDR of DRE (0.01, 95% CI: 0.01-0.02) was significantly lower than that of PSA (0.03, 95% CI 0.02-0.03; p < 0.05) and the combination of DRE and PSA (0.03, 95% CI 0.02-0.04; p < 0.05). The screening strategy combining DRE and PSA was not different to that of PSA alone in terms of CDR (p = 0.5) and PPV (p = 0.5). CONCLUSIONS AND CLINICAL IMPLICATIONS: Our comprehensive review and meta-analysis indicates that both as an independent test and as a supplementary measure to PSA for PCa detection, DRE exhibits a notably low diagnostic value. The collective findings from the included studies suggest that, in the absence of clinical symptoms and signs, DRE could be potentially omitted from PCa screening and early detection strategies. PATIENT SUMMARY: Our review shows that the screening performance of digital rectal examination for detection of prostate cancer is not particularly impressive, suggesting that it might not be necessary to conduct this examination routinely.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Matsukawa A, Yanagisawa T, Bekku K, et al. Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2024. PMID: 38182488. doi:10.1016/j.euo.2023.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。